Introduction: the epidemic of uncontrolled PPI use
Proton pump inhibitors (PPI) — omeprazole, pantoprazole, esomeprazole, rabeprazole, lansoprazole — are among the three most prescribed drug classes in the world. According to OECD Health Statistics 2024, in the United States, Germany, the United Kingdom, Italy, and Spain, 8% to 15% of the adult population takes PPI continuously for more than 12 months. In OECD countries, up to half of these prescriptions are not reassessed for years — the prescription becomes automatic.
This drug class was developed in the 1980s for acute, time-limited conditions: erosive esophagitis (8 weeks), peptic ulcer disease (4–8 weeks), H. pylori eradication (10–14 days), and stress-ulcer prophylaxis in the ICU. Over 40 years, indications have expanded to “functional dyspepsia,” “stress-related heartburn,” and “NSAID cover in a young patient without risk factors” — most of these extensions are not supported by an evidence base.
Core idea of the md_pereligyn protocol: PPI is a powerful temporary tool, not a baseline strategy. Chronic use (>1 year) is associated with three independent types of kidney injury, as well as hypomagnesemia, B12 deficiency, osteoporosis, increased risk of C. difficile, pneumonia, and dementia. In most patients on chronic PPI, the indications are no longer active and step-down to an H2 blocker or antacid is possible.
In the Atherosclerosis Risk in Communities cohort (n≈10 500), long-term PPI use was associated with a 1.5-fold increase in the risk of chronic kidney disease compared with non-users (Lazarus B, JAMA Intern Med 2016, PMID 26752337). Twice-daily use increased risk by 46%, once-daily use by 15% (a classic dose-response effect, Xie Y, J Am Soc Nephrol 2016, PMID 27000957).
🌀
Three Mechanisms of Kidney Injury
PPI injure the kidney through three independent pathways, two of which are clinically asymptomatic and are detected only by laboratory screening.
▸Mechanism 1 — acute interstitial nephritis (AIN). An immune-allergic reaction to the PPI or its metabolite. It occurs during the first 6–12 weeks of use. The classic triad of “fever + rash + eosinophilia” is seen in less than 20% of cases — most AIN cases occur without eosinophiluria, which distinguishes it from NSAID-induced AIN (Klatte DCF, Gastroenterology 2017, PMID 28735782). The marker is an unexplained decline in eGFR without an alternative diagnosis. ▸Mechanism 2 — repeated subclinical AIN episodes with tubulointerstitial scarring. Each small episode recovers clinically but leaves fibrosis behind. Over years this produces a chronic decline in eGFR without a documented episode of acute kidney injury in the history (Xie Y, Kidney Int 2017, PMID 28237506). This mechanism explains the increased CKD risk in cohort data. ▸Mechanism 3 — hypomagnesemia and nephrocalcinosis. PPI block the intestinal transporter TRPM6 and reduce magnesium absorption. In ~20% of patients on chronic therapy, hypomagnesemia (Mg <0.7 mmol/L) develops. Long-term magnesium deficiency causes secondary hyperparathyroidism, calcium mobilization from bone, deposition in soft tissues, and nephrocalcinosis.
These three mechanisms can occur in parallel in the same patient. Screening during chronic PPI use should include creatinine, eGFR, magnesium, calcium, B12 — every 6–12 months.
🌀
Drivers of Hidden Risk
Eight factors increase the likelihood of PPI-related kidney injury. The more factors are combined, the stricter monitoring should be.
•Duration of use longer than 12 months — a linear increase in CKD frequency in VA cohorts (n=144 000); each additional year adds 5–10% to relative risk. •Twice-daily use versus once-daily use — CKD risk increases by 46% versus 15%. Most patients on a BID regimen can be switched to once-daily dosing after 8 weeks of erosive esophagitis treatment. •Age over 65 years — narrow tubular reserve, polypharmacy, and reduced clearance of the PPI itself. •Concomitant stage 3 CKD or higher — reduced PPI clearance and accumulation of the active metabolite. •Serum magnesium below 0.7 mmol/L on monitoring — seen in every fifth patient on chronic therapy; often presents with tetany, calf cramps, and arrhythmias. •Concomitant NSAID use — AIN risk is additive, and gastro-“protection” is illusory. •Prescription “just in case” without erosive esophagitis — in patients without erosions and without BID indications, step-down is safe. •Polypharmacy with 5+ medications — each may increase the immunogenicity of PPI metabolites.
🌀
Early Biomarkers
Chronic PPI use requires active screening — most complications remain asymptomatic for a long time.
▸Creatinine increase of more than 26 μmol/L within 48 hours during the first 12 weeks — a KDIGO criterion for AKI; the typical scenario for mechanism 1 AIN (KDIGO 2024, Kidney Int Suppl, PMID 37879905). ▸eGFR decline of more than 25% from baseline over 6–12 months of use without an alternative explanation — a reason to discontinue or step down. ▸Serum magnesium below 0.7 mmol/L with tetany, calf muscle cramps, or arrhythmia. ▸Serum calcium below 2.2 mmol/L with preserved parathyroid function — hypocalcemia from secondary Mg deficiency. ▸Serum B12 below 200 pg/mL after 2–3 years of use — cobalamin malabsorption due to hypoacidity. ▸Ferritin and serum iron — hypochlorhydria reduces non-heme iron absorption. ▸Eosinophiluria — a less sensitive marker for PPI-AIN (present in only 20% of cases), but when positive, it has high specificity. ▸Microalbuminuria — an early indicator of tubulointerstitial injury.
🌀
Holistic Protocol for Safe Use
The principle of the md_pereligyn protocol: PPI is indicated for time-limited conditions, and most patients on chronic use can be transitioned to step-down or functional GERD treatment strategies.
### 1. Duration Limits by Indication
▸Erosive esophagitis — standard course 8 weeks, follow-up EGD, and step-down if healed. ▸Peptic ulcer disease — 4–8 weeks depending on ulcer size, with follow-up EGD. ▸Non-erosive GERD (NERD), functional dyspepsia — course no longer than 4–8 weeks, then step-down. ▸H. pylori eradication — 10–14 days as part of triple/quadruple therapy. ▸NSAID-course cover in patients at high gastrointestinal risk (≥65 years, prior ulcer, anticoagulants) — only for the duration of the NSAID course. ▸Chronic use (>12 months) is justified only for: severe erosive esophagitis, Barrett’s syndrome, Zollinger–Ellison syndrome.
### 2. Step-down to Famotidine and Antacids
In patients on chronic PPI without active indications, the transition is performed gradually over 2–4 weeks to avoid rebound hypersecretion (a sharp return of heartburn after discontinuation).
▸Step 1 — dose reduction — for example, omeprazole 40 mg → 20 mg → 10 mg, 1–2 weeks at each step. ▸Step 2 — transition to an H2 blocker — famotidine 20–40 mg 1–2 times/day, for 2–4 weeks. ▸Step 3 — antacids on demand — algeldrate/magnesium hydroxide, calcium carbonate — for episodic heartburn. ▸Step 4 — discontinuation while continuing the functional protocol (see below).
### 3. Functional GERD Treatment Protocol
In most patients with functional GERD, elimination of triggers produces sustained improvement without chronic PPI.
▸Dinner no later than 3 hours before sleep — the main factor in nocturnal reflux. ▸Elevation of the head of the bed by 15 cm (with a physical wedge, not a pillow) — for nocturnal symptoms. ▸Body weight reduction by 5–10% if BMI >27 — waist circumference directly correlates with gastric pressure and lower esophageal sphincter competence. ▸BMI reduction in visceral obesity — intra-abdominal pressure and hiatal hernia are a common cause of “refractory” GERD. ▸Elimination/reduction of triggers — alcohol, coffee on an empty stomach, chocolate, mint, tomato sauces, fatty and fried foods, carbonated drinks. ▸Smoking cessation — nicotine reduces lower esophageal sphincter tone. ▸Right body position on the left side during sleep — anatomically reduces reflux. ▸Sugar-free chewing gum after meals — stimulation of salivation neutralizes acid in the esophagus.
### 4. Repletion of Deficiencies During Use
▸Magnesium citrate or glycinate 320 mg (women) / 420 mg (men) daily during PPI use longer than 12 months. ▸Vitamin B12 (methylcobalamin) 500–1000 μg sublingually during PPI use >2 years. ▸Vitamin D3 + K2 — optimization of bone metabolism (PPI is associated with osteoporosis risk). ▸Calcium citrate (not carbonate) — better absorbed under hypoacidic conditions. ▸Iron — if iron-deficiency anemia is identified, switch to chelated forms (iron bisglycinate). ▸Probiotics — reduce the risk of C. difficile-associated diarrhea in patients on chronic PPI.
### 5. Monitoring During Chronic Use (if Step-down Is Not Possible)
▸Creatinine, eGFR, potassium every 6 months. ▸Magnesium and B12 every 6–12 months. ▸Densitometry every 2 years — bone density monitoring. ▸Ferritin and complete blood count annually. ▸Microalbuminuria once a year — an early marker of tubulointerstitial injury.
🌀
What Does NOT Work (and Why)
▸“Protective PPI course just in case during stress” — has no evidence base in patients without erosive esophagitis and without risk factors. It creates chronic dependence. ▸Abrupt PPI discontinuation without step-down — causes rebound hypersecretion and return of heartburn, which is often interpreted as “the disease has returned” and leads to resumption of chronic use. ▸Twice-daily use (BID) in a patient who has managed for years on once-daily dosing — increases kidney risk by 30% compared with a QD regimen without additional clinical benefit. ▸Switching omeprazole to “newer” esomeprazole to reduce risk — all PPI in the class share the same immunogenic mechanism; between-drug differences in nephro-risk are small. ▸Antacids as a “safe” alternative on 24/7 use — aluminum-containing antacids in CKD carry a risk of aluminum encephalopathy; magnesium-containing antacids can cause hypermagnesemia in patients with CKD. ▸Homeopathic “mucosal protectors” instead of an evidence-based step-down strategy — have no proven efficacy and create a false sense of control.
🌀
When to Seek Care
▸Chronic PPI use >12 months without a clear active indication ▸Twice-daily use (BID) without confirmed erosive esophagitis or Barrett’s syndrome ▸Symptoms of magnesium deficiency: tetany, calf cramps, arrhythmias, fatigue ▸Symptoms of B12 deficiency: paresthesias, fatigue, cognitive decline ▸Unexplained eGFR decline during PPI use ▸Desire to transition from chronic PPI to a functional GERD treatment protocol ▸Concomitant use of NSAIDs, ACE inhibitors/ARB, diuretics (increased kidney risk)
I perform a full nephro-metabolic screening (creatinine, eGFR, cystatin C, magnesium, calcium, B12, ferritin, microalbuminuria, densitometry), reassess the indications for PPI, and create a personalized step-down protocol with functional GERD treatment.
🌀
Conclusion
PPI is a powerful temporary tool, not lifelong therapy. An eight-week course for erosive esophagitis is safe; eight years without reassessing indications is a path to stage 3 CKD, hypomagnesemia, B12 deficiency, and osteoporosis without a single obvious symptom.
Omeprazole prescribed “just in case for gastritis” can, over ten years, quietly turn the kidney into an organ for nephrology screening. Most patients on chronic use can be transitioned to step-down with famotidine and antacids while simultaneously using a functional GERD treatment protocol — weight reduction, earlier dinner, head-of-bed elevation, and trigger elimination.
The goal is to treat the cause of reflux, not chemically block normal gastric physiology for decades.
🌀
Sources
▸Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. *JAMA Intern Med* 2016;176:238–246. PMID 26752337 ▸Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients. *CMAJ Open* 2015;3:E166–E171. PMID 26389094 ▸Xie Y, Bowe B, Li T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. *J Am Soc Nephrol* 2016;27:3153–3163. PMID 27000957 ▸Xie Y, Bowe B, Li T, et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. *Kidney Int* 2017;91:1482–1494. PMID 28237506 ▸Klatte DCF, Gasparini A, Xu H, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. *Gastroenterology* 2017;153:702–710. PMID 28735782 ▸KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl* 2024. PMID 37879905
Related articles: [Endothelium: the Foundation of Vascular Health](/blog/endothelium-foundation-vascular-health), [Cholesterol Without Statins](/blog/kholesterin-bez-statinov).
🌀
FAQ
I have been taking omeprazole for 5 years, and I am afraid to stop — the heartburn will come back. How can I stop safely? Use step-down over 4–6 weeks: omeprazole 40→20→10 mg (2 weeks each), then famotidine 20–40 mg for another 2–4 weeks, then antacids on demand. In parallel: dinner 3 hours before sleep, head-of-bed elevation by 15 cm, weight reduction if BMI >27, elimination of triggers (alcohol, coffee on an empty stomach, chocolate, mint). Rebound hypersecretion during gradual discontinuation usually lasts 1–2 weeks and resolves. Abrupt discontinuation causes strong rebound and should be avoided.
Can I take a PPI as “cover” during a 5-day course of ibuprofen? In a young patient without risk factors (no history of ulcer, no anticoagulants, no glucocorticoids) — it is not needed. The gastrointestinal risk of a 5-day course of ibuprofen is low. PPI is indicated for: age ≥65, history of ulcer, concomitant aspirin/anticoagulants/glucocorticoids, prolonged NSAID course (>10 days). Note: PPI protects the stomach, but does not protect the kidney — with the combination of PPI + NSAID, kidney risk actually increases.
Which is better — omeprazole or esomeprazole? There is no clinically significant difference. Esomeprazole is the S-isomer of omeprazole, and its marketing advantage over generic omeprazole is mostly economic. All PPI in the class share the same mechanism, the same spectrum of adverse effects, and the same kidney risk during chronic use. The choice of drug rarely has clinical significance — what matters is the indication, duration, and regimen (QD vs BID).
Is PPI-related hypomagnesemia dangerous, and how can it be recognized? Yes, it is dangerous. Symptoms: tetany, calf muscle cramps (especially at night), paresthesias, arrhythmias, increased fatigue, anxiety. Laboratory: serum magnesium <0.7 mmol/L; ideally, add RBC magnesium (more sensitive). Prevention: magnesium citrate or glycinate 320 mg (women) / 420 mg (men) daily during PPI use >12 months. In significant hypomagnesemia, PPI discontinuation/step-down is mandatory; magnesium repletion alone does not solve the problem.
If I have Barrett’s syndrome, can I stop PPI? No. Barrett’s syndrome is an absolute indication for lifelong acid suppression with PPI to reduce the risk of progression to dysplasia and esophageal adenocarcinoma. In this case, the goal is not to “stop,” but to minimize the risks of chronic use: once-daily use (QD), not twice-daily (BID); regular monitoring (creatinine, eGFR, magnesium, B12, densitometry every 6–12 months); repletion of Mg, B12, D3+K2; body weight and trigger control to reduce the dose.
*This article is for informational purposes only and is not a substitute for professional medical advice. Discuss any nutraceutical, medication adjustment, or diagnostic procedure with your treating physician before starting.*
